Navidea Appoints Anton Gueth Chairman of the Board
January 11 2016 - 06:30AM
Business Wire
Navidea Biopharmaceuticals, Inc. (NYSE MKT:NAVB), announced that
its Board of Directors has appointed board member Anton Gueth to
the position of Chairman. Mr. Gueth succeeds Gordon Troup who
joined Navidea's Board of Directors in July 2008 and was named as
Chairman of the Board in August 2011. Although Mr. Troup has
stepped down as Chairman, he continues to serve as a director on
the Board.
“For some time now, I have felt that as we progressed our
strategy to unlock the full potential of our Manocept™ technology
platform, the time would come for a new and highly qualified
industry leader to assume the role of Navidea’s Chairman,” said Mr.
Troup. “We believe Anton will provide a strong commercial presence
on the Board and help strengthen our ability to transform Navidea
into a leader in the development and commercialization of both
immunodiagnostic and immunotherapeutic products.”
Mr. Gueth brings over 30 years of global finance and operating
experience in the pharmaceutical and healthcare industries. He is
currently Managing Director of EVOLUTION Life Science
Partners. He is also the founder and Managing Partner of Gueth
Consulting LLC, a consulting firm focusing on pharmaceutical and
biotechnology clients in the areas of licensing, early stage
financing and alliance management and was previously a Managing
Director of Burrill Securities. His career includes nearly 19 years
with Eli Lilly and Company ("Lilly"), most recently as director
of Alliance Management. He also served as General Manager of
Lilly's African and Middle Eastern operations; Vice President
of Financial Planning and Treasury of PCS Health Systems; as well
as other sales, marketing, operations and financial positions. Mr.
Gueth earned a Masters Degree in agricultural economics from
the Justus Liebig University in Giessen, Germany, as well as a
Masters Degree in public affairs from Indiana University. He
is currently a member of the Board of Directors of Antares
Pharma.
“I am excited to take on this expanded role and look forward to
partnering with Rick and the rest of the Board to advance our
immunotherapeutic program and extend our commercial success to
unlock the full potential of the Manocept platform. I share Rick’s
commitment to improving our corporate governance and shareholder
engagement in 2016 as we believe good corporate governance yields
improved value for shareholders," said Mr. Gueth.
About NavideaNavidea Biopharmaceuticals, Inc. (NYSE MKT:
NAVB) is a biopharmaceutical company focused on the development and
commercialization of precision immunodiagnostic agents and
immunotherapeutics. Navidea is developing multiple
precision-targeted products and platforms including Manocept™ and
NAV4694 to help identify the sites and pathways of undetected
disease and enable better diagnostic accuracy, clinical
decision-making, targeted treatment and, ultimately, patient care.
Lymphoseek® (technetium Tc 99m tilmanocept) injection, Navidea’s
first commercial product from the Manocept platform, was approved
by the FDA in March 2013 and in Europe in November 2014. Navidea’s
strategy is to deliver superior growth and shareholder return by
bringing to market novel products and advancing the Company’s
pipeline through global partnering and commercialization efforts.
For more information, please visit www.navidea.com.
The Private Securities Litigation Reform Act of 1995 (the Act)
provides a safe harbor for forward-looking statements made by or on
behalf of the Company. Statements in this news release, which
relate to other than strictly historical facts, such as statements
about the Company’s plans and strategies, expectations for future
financial performance, new and existing products and technologies,
anticipated clinical and regulatory pathways, and markets for the
Company’s products are forward-looking statements within the
meaning of the Act. The words “believe,” “expect,” “anticipate,”
“estimate,” “project,” and similar expressions identify
forward-looking statements that speak only as of the date hereof.
Investors are cautioned that such statements involve risks and
uncertainties that could cause actual results to differ materially
from historical or anticipated results due to many factors
including, but not limited to, the Company’s continuing operating
losses, uncertainty of market acceptance of its products, reliance
on third party manufacturers, accumulated deficit, future capital
needs, uncertainty of capital funding, dependence on limited
product line and distribution channels, competition, limited
marketing and manufacturing experience, risks of development of new
products, regulatory risks and other risks detailed in the
Company’s most recent Annual Report on Form 10-K and other
Securities and Exchange Commission filings. The Company undertakes
no obligation to publicly update or revise any forward-looking
statements.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20160111005490/en/
Navidea BiopharmaceuticalsInvestorsTom Baker,
617-532-0624tbaker@navidea.comorMediaSharon Correia, 978-655-2686Associate
Director, Corporate CommunicationsorDavid Shull or Chris Hippolyte,
858-717-2310david.schull@russopartnersllc.comChris.hippolyte@russopartnersllc.com
Navidea Biopharmaceuticals (AMEX:NAVB)
Historical Stock Chart
From Feb 2024 to Mar 2024
Navidea Biopharmaceuticals (AMEX:NAVB)
Historical Stock Chart
From Mar 2023 to Mar 2024